Search for a trial

Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients

To determine the relation between tumor tissue phosphoproteomic profiles and progression-free survival (PFS) in patients with advanced RCC

A randomized phase I/II study of standard chemotherapy (cisplatin and pemetrexed) with or without Axitinib in patients with malignant mesothelioma:
interim biopsy analysis and Dynamic Contrast Enhanced MRI to determine efficacy.

To test the impact of the addition of axitinib to standard chemotherapy treatment on histology samples

Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence

This study has been transitioned to CTIS with ID 2024-515825-27-00 check the CTIS register for the current data. To investigate efficacy of neoadjuvant axitinib and avelumab in patients with localized renal cell carcinoma with moderate to high risk…

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Sub-study APhase 1b:To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to determine the RP2D for the combination. Phase 2:To assess the durable ORR of sasanlimab in combination with encorafenib…

A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM
STUDY OF AVELUMAb (MSB0010718C) IN COMBINATION WITH AXITINIB
(INLYTA®) VERSUS SUNITINIB (SUTENT®) ) MONOTHERAPY IN THE
FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL
CARCINOMA

Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…